Skip to main content

5th generation cephalosporin

Ceftobiprole is a fifth-generation cephalosporin antibiotic with activity against MRSA, penicillin-resistant, Pseudomonas aeruginosa, and enterococci.

It is on Fast track for FDA approval. Ceftobiprole has already been approved for use in Canada and Switzerland.


Ceftobiprole is the first, broad-spectrum, anti-MRSA cephalosporin. It is also the first of antimicrobials to include anti-MRSA and anti-Pseudomonas activity in the spectrum of its coverage - providing single coverage for both.

 The dosing is 500 mg IV every 8 hours or every 12 hours.

 Dosing adjustments may be necessary in patients with renal insufficiency.

Labels:

Comments

Post a Comment

Popular posts from this blog

The 100 essentials in icu and anesthesia

The most visual experience in anesthesia and critical care education  The 100 essentials of anesthesia and critical care  COMING VERY SOON  stay tuned 
Post a Comment
Read more

Driving Pressure in ARDS: A new concept!

Driving Pressure and Survival in the Acute Respiratory Distress Syndrome Marcelo B.P. Amato, M.D., Maureen O. Meade, M.D., Arthur S. Slutsky, M.D., Laurent Brochard, M.D., Eduardo L.V. Costa, M.D., David A. Schoenfeld, Ph.D., Thomas E. Stewart, M.D., Matthias Briel, M.D., Daniel Talmor, M.D., M.P.H., Alain Mercat, M.D., Jean-Christophe M. Richard, M.D., Carlos R.R. Carvalho, M.D., and Roy G. Brower, M.D. N Engl J Med 2015; 372:747-755 February 19, 2015 DOI: 10.1056/NEJMsa1410639 BACKGROUND Mechanical-ventilation strategies that use lower end-inspiratory (plateau) airway pressures, lower tidal volumes (V T ), and higher positive end-expiratory pressures (PEEPs) can improve survival in patients with the acute respiratory distress syndrome (ARDS), but the relative importance of each of these components is uncertain. Because respiratory-system compliance (C RS ) is strongly related to the volume of aerated remaining functional lung during disease (termed functional lung size)...
6 comments
Read more